Sign up
Pharma Capital

Nemaura Medical targeting year-end for UK launch of its glucose monitor

Faz Chowdhury, chief executive of Nemaura Medical Inc (NASDAQ:NMRD), spoke to Proactive London's Andrew Scott to update on their European and FDA trials as work continues towards the launch in the UK of their non-invasive glucose monitor by the end of the year.

''We believe it'll be the world's first non-invasive glucose monitoring system''.

''It's a continuous monitor, you place it on the arm and it provides a read-out every five minutes''.

''It's a technology we've been developing over the last seven years or so ... we're in the process of awaiting CE approval in the UK and we're anticipating a soft launch in the UK by the end of the year''.


View full NMRD profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.